Lakefront Biotherapeutics (LKFT)
Develops and acquires autoimmune T-cell engager medicines with Gilead.
Something off on this page? Send us feedback.
Develops acquired autoimmune T-cell engagers, led by gamgertamig, while partnering with Gilead on later development and commercialization. Its model combines selective asset transactions with early clinical execution rather than product sales.
Builds a development-stage biotechnology pipeline by acquiring or licensing clinically de-risked medicines and advancing selected early clinical studies. The core program, gamgertamig, is a subcutaneous BCMAxCD3 T-cell engager being studied in autoimmune cytopenias and seropositive autoimmune diseases; a selective TYK2 small-molecule program is under strategic review. Residual economics include royalties, earn-outs, and transitional supply from the transferred Jyseleca business.
Executes asset transactions and early development while using Gilead for registrational studies and commercialization of gamgertamig outside Keymed's Greater China territories. The model depends on clinical progress, external trial and supply partners, and Gilead's collaboration and opt-in rights; no approved proprietary product remains in the current development portfolio.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 11, 2026 | Morgan Stanley | Reiterate | Equal Weight | $30 | $26 |
| Jul 10, 2026 | Morgan Stanley | Target | $30 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.60B · Total debt $7.4M · Total assets $3.89B · Shareholders' equity $3.78B
- Revenue
- $14.1M
- Operating income
- −$50.5M
- Net income
- $2.4M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
No ownership filings on record for this listing.
- Cullinan Therapeutics
Dual T-cell engagers target the most overlapping autoimmune indications.
- Cabaletta Bio
CD19 CAR-T offers an immune-reset alternative in myositis and pemphigus.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lakefront Biotherapeutics | $28.96 | +0.50% | $1.90B | 2.7 | — | 1.7 | −81.7% |
| Cullinan Therapeutics | $22.16 | −0.89% | $1.37B | — | — | — | — |
| Cabaletta Bio | $3.60 | +0.71% | $582.1M | — | — | — | — |